These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27896510)

  • 1. Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
    Mehta AM; Huitema AD; Burger JW; Brandt-Kerkhof AR; van den Heuvel SF; Verwaal VJ
    Ann Surg Oncol; 2017 Apr; 24(4):990-997. PubMed ID: 27896510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
    Mehta AM; Van den Hoven JM; Rosing H; Hillebrand MJ; Nuijen B; Huitema AD; Beijnen JH; Verwaal VJ
    Int J Pharm; 2015 Feb; 479(1):23-7. PubMed ID: 25535649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
    J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
    Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
    Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
    Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: Toward routine preoperative dosage of Von Willebrand factor?
    Delhorme JB; Sattler L; Severac F; Triki E; Gross I; Romain B; Rohr S; Grunebaum L; Brigand C
    Eur J Surg Oncol; 2017 Jun; 43(6):1095-1101. PubMed ID: 28209329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.
    Ceelen W; De Somer F; Van Nieuwenhove Y; Vande Putte D; Pattyn P
    Eur J Surg Oncol; 2013 Jul; 39(7):754-9. PubMed ID: 22878060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer.
    Müller H; Hotopp T; Tofeili A; Wutke K
    Hepatogastroenterology; 2014 May; 61(131):703-6. PubMed ID: 26176060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
    Klaver YL; de Hingh IH; Boot H; Verwaal VJ
    J Surg Oncol; 2011 Apr; 103(5):431-4. PubMed ID: 21400529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
    de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
    BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
    Bhandare M; Patil P; Pai V; Bhamre R; Engineer R; Ostwal V; Saklani A
    Clin Colorectal Cancer; 2017 Jun; 16(2):e1-e6. PubMed ID: 27670895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
    Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
    Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
    Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
    Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.